In NSCLC, roughly one third of the patients present mutation in the KRAS oncogene, with G12C substitution being the most frequent and constituting a negative predictive factor for response to first-line cisplatin therapy, as recently reported by our group [30]. This evidence concerns the gene KRAS and non-small cell lung carcinoma.